∗DENT Neurologic Institute

†University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY.

Address correspondence and reprint requests to Anna G. Mattle, PharmD, MS, 3980 Sheridan Drive, Suite 304, Amherst, NY 14226; E-mail: [email protected]

Conflicts of Interest and Source of Funding: B.M. has received personal compensation for consulting, speaking, research affiliation, or other activities with Acorda Therapeutics, Banner Life Sciences, Biogen, Celgene, EMD Serono, Genentech, Merz, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals, and TerSera Therapeutics. L.M. has received personal compensation for consulting, serving on a scientific advisory board, speaking, research affiliation, or other activities with Alder Pharmaceuticals, Allergan, Amgen, Avanir, Biohaven, Boston Biomedical Inc, CellDex, DelMar Pharmaceuticals, electroCore, Novartis, Orbis Pharmaceuticals, Promius, Teva Pharmaceuticals, and Jushi, and has financial interest in Jushi. No Jushi products were used by patients in this study. The other authors have nothing to disclose. This project was made possible by the support from the Harry Dent Family Foundation, Inc, a 501(c) 3 nonprofit dedicated to advancing neuroscience research.

Presentations: This project was previously presented at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, PA.